Intravenous infusion of activated autologous macrophages armed with anti-CD20 monoclonal antibodies can yield sustained molecular remission in CLL.

被引：0
|
作者：
Sutton, L
Azar, N
Cazin, B
Baudet, S
Reynes, N
Tardy, D
Abastado, JP
Romet-Lemonne, JL
Maloum, K
机构：
[1] Hop La Pitie Salpetriere, Paris, France
[2] Claude Huriez Hosp, Lille, France
[3] Immuno Designed Mol, Paris, France
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3360
引用
收藏
页码：808A / 808A
页数：1
相关论文
共 22 条
  • [1] Idiopathic systemic vasculitis (IVS) remission after treatment with anti-CD20 monoclonal antibodies
    Roccatello, D.
    Rossi, D.
    Baldovino, S.
    Alpa, M.
    Naretto, C.
    Brosio, P.
    Napoli, F.
    La Grotta, R.
    Cavallo, R.
    Giachino, O.
    Sena, L. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 382 - 383
  • [2] Autologous activated macrophages (MAK™) coated ex vivo with humanized anti-CD20 monoclonal antibodies can eradicate minimal residual disease in chronic lymphocytic leukaemia in clinical response
    Sutton, Laurent
    Chaoui, Driss
    Cazin, Bruno
    Azar, Nabih
    Chokri, Mohamed
    Romet-Lemonne, Jean-Loup
    Maloum, Karim
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (06) : 996 - 998
  • [3] BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naive elderly patients with CLL
    Rogers, Andrew
    Woyach, Jennifer A.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [4] Anti-CD20 monoclonal antibody dependent phagocytosis of chronic lymphocytic leukemia cells by autologous macrophages
    Zent, Clive
    Church, Amy
    VanDerMeid, Karl
    Baig, Nisar
    Baran, Andrea
    Witzig, Thomas
    Nowakowski, Grzegorz
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 : 166 - 166
  • [5] Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages
    Church, A. K.
    VanDerMeid, K. R.
    Baig, N. A.
    Baran, A. M.
    Witzig, T. E.
    Nowakowski, G. S.
    Zent, C. S.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2016, 183 (01): : 90 - 101
  • [6] Treatment of severe chronic lymphocytic leukemia in residual disease stage with autologous macrophages activated and associated to humanized anti-CD20 antibodies.
    Sutton, L
    Cazin, B
    Azar, N
    Baudet, S
    Tardy, D
    Romet-Lemonne, JL
    Maloum, K
    [J]. BLOOD, 2000, 96 (11) : 295B - 295B
  • [7] Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia
    Faurschou, M
    Hasselbach, HC
    Nielsen, OJ
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 66 (06) : 408 - 411
  • [8] Comparative Safety Analysis of Currently Approved Anti-CD20 Monoclonal Antibodies for First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
    Mwamburi, Mkaya
    Bal, Vasudha
    Cascella, Teresa
    Shah, Anshul
    Nanavaty, Merena
    Gala, Smeet
    [J]. BLOOD, 2016, 128 (22)
  • [9] Comparative safety analysis of currently approved anti-CD20 monoclonal antibodies for first line treatment of chronic lymphocytic leukemia (CLL)
    Gala, Smeet
    Mwamburi, Mkaya
    Bal, Vasudha
    Cascella, Teresa
    Shah, Anshul
    Nanavaty, Merena
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 : 21 - 22
  • [10] Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
    Le Garff-Tavernier, M.
    Decocq, J.
    de Romeuf, C.
    Parizot, C.
    Dutertre, C. A.
    Chapiro, E.
    Davi, F.
    Debre, P.
    Prost, J. F.
    Teillaud, J. L.
    Merle-Beral, H.
    Vieillard, V.
    [J]. LEUKEMIA, 2011, 25 (01) : 101 - 109
123